Lyra Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
01/11/2024 14:14
* Lyra Therapeutics Inc LYRA.OQ LYRA.O is expected
to show a
fall in quarterly revenue when it reports results on November 5
(estimated) for the period ending September 30 2024
* The Watertown Massachusetts-based company is expected to
report
a 41.2% decrease in revenue to $320 thousand from $544 thousand
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Lyra Therapeutics Inc is
for a
loss of 23 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Lyra
Therapeutics
Inc is $1.25, above its last closing price of $0.27.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.33 -0.33 -0.74 Missed -125.6
Jan. 1 0001 -0.27 -0.26 -0.35 Missed -33.6
Dec. 31 2023 -0.31 -0.22 Beat 30.2
Sep. 30 2023 -0.31 -0.32 -0.27 Beat 15.1
Jun. -0.40 -0.42 -0.32 Beat 24.4
30 2023
Mar. 31 2023 -0.36 -0.36 -0.44 Missed -20.5
Dec. 31 2022 -0.39 -0.41 -0.38 Beat 8.2
Sep. 30 2022 -0.46 -0.44 -0.40 Beat 9.1
This summary was machine generated November 1 at 14:14 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)